Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Professor Ning Li is the associate dean of Chinese Materia Medica of Shenyang Pharmaceutical University, the "Youth talent" of Liao Ning Revitalization Talents Program, the "Talent of Hundred level" of Liaoning Bai Qian Wan Talents Program, the "Leading talent" of both Shenyang High-Level Talent Program and Xinjiang Uygur Autonomous Region. She has focused on the research of chemoprevention of critical diseases, especially the neurodegenerative disease and cancer, through post-transcriptional mechanism on the perspective view of ‘preventive treatment strategy’ of the Traditional Chinese theory. She has hosted seven projects of National Natural Science Foundation of China and published more than 120 SCI papers on famous academic journals, born several prizes like the "First Prize of Provincial Science and technology progress award", and obtained the authorization of 20 invention patents. Professor Caiyun Fu obtained her PhD degree from Lanzhou university and currently is a professor of biology and deputy director of the College of Life Sciences and Medicine, director of the Research Institute for Polypeptide and Protein Pharmaceutical Products, Zhejiang Sci-Tech University. Her research interests focus on screening and identification of tumor targets and exploration of targeted intervention and developing new drugs of peptides by synthetic biology. To date she has published 34 academic papers as corresponding author or first author in international high-impact peer-reviewed journals, including Proceedings of the National Academy of Sciences of the United States of America, Advanced Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, Signal Transduction and Targeted Therapy, etc

• 1. Thiazole, a privileged scaffold in new drug discovery 2. Chalcone: Diverse biological activities and structure-activity relationships 3. Privileged chalcone scaffolds in drug discovery 4. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs 5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids 6. Triazoles: a privileged scaffold in drug design and novel drug discovery 7. Oxazolidinone scaffolds in drug discovery and development 8. Indole and indoline scaffolds in drug discovery 9. Cyanopyridine as a privileged scaffold in drug discovery 10. Indazole as privileged scaffold in drug discovery 11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry 12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine demethylase 1 inhibitors 13. Applications of piperazine scaffold in drug design 14. Thiols as a privileged scaffold against metallo-β-lactamases 15. Tetrahydro-β-carboline scaffold in drug discovery 16. Benzoxaborole: a privileged scaffold for drug discovery 17. Privileged scaffolds in anti-diabetic drug discovery 18. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS 19. 2-Aminopyrimidine: a privileged scaffold in kinase drug discovery 20. Alzheimer’s disease therapeutics: current strategies and future directions 21. Sulfonyl fluorides as warheads in drug discovery 22. α,β-Bifunctionalized carbonyl compounds as privileged motifs in drug discovery and their synthetic protocols 23. Diarylpyrimidines and related analogs as antiviral agents 24. Organic synthetic methodology-based new scaffold in drug discovery 25. Natural resource of anti-human immunodeficiency virus leading compounds: tigliane diterpenoids 26. Biological phenethyl glycosides from plants 27. Triterpenoids and saponins in drug discovery 28. Casbene-derived diterpenoids 29. Quassinoids: phytochemistry and antitumor prospect 30. Structural diversity, biosynthesis, and biological functions of meroterpenoids from microbial metabolites 31. Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein 32. Peptide and peptide-based drugs 33. Stapled peptides for new drug discovery 34. Current status and trends in research and development of polypeptide drugs 35. Unique opportunities of metal scaffolds in drug design 36. N-Heterocyclic carbene as privileged scaffold in medicinal inorganic chemistry 37. Selenium-containing heterocycles 38. Computational methods for scaffold hopping

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Professor Ning Li is the associate dean of Chinese Materia Medica of Shenyang Pharmaceutical University, the "Youth talent" of Liao Ning Revitalization Talents Program, the "Talent of Hundred level" of Liaoning Bai Qian Wan Talents Program, the "Leading talent" of both Shenyang High-Level Talent Program and Xinjiang Uygur Autonomous Region. She has focused on the research of chemoprevention of critical diseases, especially the neurodegenerative disease and cancer, through post-transcriptional mechanism on the perspective view of ‘preventive treatment strategy’ of the Traditional Chinese theory. She has hosted seven projects of National Natural Science Foundation of China and published more than 120 SCI papers on famous academic journals, born several prizes like the "First Prize of Provincial Science and technology progress award", and obtained the authorization of 20 invention patents. Professor Caiyun Fu obtained her PhD degree from Lanzhou university and currently is a professor of biology and deputy director of the College of Life Sciences and Medicine, director of the Research Institute for Polypeptide and Protein Pharmaceutical Products, Zhejiang Sci-Tech University. Her research interests focus on screening and identification of tumor targets and exploration of targeted intervention and developing new drugs of peptides by synthetic biology. To date she has published 34 academic papers as corresponding author or first author in international high-impact peer-reviewed journals, including Proceedings of the National Academy of Sciences of the United States of America, Advanced Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, Signal Transduction and Targeted Therapy, etc

• 1. Thiazole, a privileged scaffold in new drug discovery 2. Chalcone: Diverse biological activities and structure-activity relationships 3. Privileged chalcone scaffolds in drug discovery 4. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs 5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids 6. Triazoles: a privileged scaffold in drug design and novel drug discovery 7. Oxazolidinone scaffolds in drug discovery and development 8. Indole and indoline scaffolds in drug discovery 9. Cyanopyridine as a privileged scaffold in drug discovery 10. Indazole as privileged scaffold in drug discovery 11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry 12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine demethylase 1 inhibitors 13. Applications of piperazine scaffold in drug design 14. Thiols as a privileged scaffold against metallo-β-lactamases 15. Tetrahydro-β-carboline scaffold in drug discovery 16. Benzoxaborole: a privileged scaffold for drug discovery 17. Privileged scaffolds in anti-diabetic drug discovery 18. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS 19. 2-Aminopyrimidine: a privileged scaffold in kinase drug discovery 20. Alzheimer’s disease therapeutics: current strategies and future directions 21. Sulfonyl fluorides as warheads in drug discovery 22. α,β-Bifunctionalized carbonyl compounds as privileged motifs in drug discovery and their synthetic protocols 23. Diarylpyrimidines and related analogs as antiviral agents 24. Organic synthetic methodology-based new scaffold in drug discovery 25. Natural resource of anti-human immunodeficiency virus leading compounds: tigliane diterpenoids 26. Biological phenethyl glycosides from plants 27. Triterpenoids and saponins in drug discovery 28. Casbene-derived diterpenoids 29. Quassinoids: phytochemistry and antitumor prospect 30. Structural diversity, biosynthesis, and biological functions of meroterpenoids from microbial metabolites 31. Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein 32. Peptide and peptide-based drugs 33. Stapled peptides for new drug discovery 34. Current status and trends in research and development of polypeptide drugs 35. Unique opportunities of metal scaffolds in drug design 36. N-Heterocyclic carbene as privileged scaffold in medicinal inorganic chemistry 37. Selenium-containing heterocycles 38. Computational methods for scaffold hopping

Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Professor Ning Li is the associate dean of Chinese Materia Medica of Shenyang Pharmaceutical University, the "Youth talent" of Liao Ning Revitalization Talents Program, the "Talent of Hundred level" of Liaoning Bai Qian Wan Talents Program, the "Leading talent" of both Shenyang High-Level Talent Program and Xinjiang Uygur Autonomous Region. She has focused on the research of chemoprevention of critical diseases, especially the neurodegenerative disease and cancer, through post-transcriptional mechanism on the perspective view of ‘preventive treatment strategy’ of the Traditional Chinese theory. She has hosted seven projects of National Natural Science Foundation of China and published more than 120 SCI papers on famous academic journals, born several prizes like the "First Prize of Provincial Science and technology progress award", and obtained the authorization of 20 invention patents. Professor Caiyun Fu obtained her PhD degree from Lanzhou university and currently is a professor of biology and deputy director of the College of Life Sciences and Medicine, director of the Research Institute for Polypeptide and Protein Pharmaceutical Products, Zhejiang Sci-Tech University. Her research interests focus on screening and identification of tumor targets and exploration of targeted intervention and developing new drugs of peptides by synthetic biology. To date she has published 34 academic papers as corresponding author or first author in international high-impact peer-reviewed journals, including Proceedings of the National Academy of Sciences of the United States of America, Advanced Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, Signal Transduction and Targeted Therapy, etc

• 1. Thiazole, a privileged scaffold in new drug discovery 2. Chalcone: Diverse biological activities and structure-activity relationships 3. Privileged chalcone scaffolds in drug discovery 4. The N-sulfonyl carboxamide moiety as a privileged structure in approved drugs 5. Scaffolds in cytotoxic drugs and novel antitumor molecules interacting with nucleic acids 6. Triazoles: a privileged scaffold in drug design and novel drug discovery 7. Oxazolidinone scaffolds in drug discovery and development 8. Indole and indoline scaffolds in drug discovery 9. Cyanopyridine as a privileged scaffold in drug discovery 10. Indazole as privileged scaffold in drug discovery 11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry 12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine demethylase 1 inhibitors 13. Applications of piperazine scaffold in drug design 14. Thiols as a privileged scaffold against metallo-β-lactamases 15. Tetrahydro-β-carboline scaffold in drug discovery 16. Benzoxaborole: a privileged scaffold for drug discovery 17. Privileged scaffolds in anti-diabetic drug discovery 18. Authentic HIV-1 integrase inhibitors for the treatment of HIV-1/AIDS 19. 2-Aminopyrimidine: a privileged scaffold in kinase drug discovery 20. Alzheimer’s disease therapeutics: current strategies and future directions 21. Sulfonyl fluorides as warheads in drug discovery 22. α,β-Bifunctionalized carbonyl compounds as privileged motifs in drug discovery and their synthetic protocols 23. Diarylpyrimidines and related analogs as antiviral agents 24. Organic synthetic methodology-based new scaffold in drug discovery 25. Natural resource of anti-human immunodeficiency virus leading compounds: tigliane diterpenoids 26. Biological phenethyl glycosides from plants 27. Triterpenoids and saponins in drug discovery 28. Casbene-derived diterpenoids 29. Quassinoids: phytochemistry and antitumor prospect 30. Structural diversity, biosynthesis, and biological functions of meroterpenoids from microbial metabolites 31. Glucocorticoid compounds in drug discovery by targeting glucocorticoid receptor protein 32. Peptide and peptide-based drugs 33. Stapled peptides for new drug discovery 34. Current status and trends in research and development of polypeptide drugs 35. Unique opportunities of metal scaffolds in drug design 36. N-Heterocyclic carbene as privileged scaffold in medicinal inorganic chemistry 37. Selenium-containing heterocycles 38. Computational methods for scaffold hopping